hit counter
Atara Biotherapeutics, Inc. (ATRA) Stock News Sentiment & Price - Sentifly
ATRA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Atara Biotherapeutics, Inc. (ATRA)

USA
Biotechnology
NASDAQ
ATRA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ATRA Latest news
Business Wire
Neutral
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
2021-10-13 07:30

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new translational data based on magnetization transfer ratio (MTR) and updated Phase 1 open-label extension (OLE) clinical data in patients with progressive multiple sclerosis (MS) treated with ATA188

Business Wire
Neutral
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
2021-10-04 07:30

SOUTH SAN FRANCISCO, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive

Business Wire
Neutral
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-10-01 18:14

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 104,386 restricted stock units of Atara's common stock to 16 newly hired employees and stock options to purchase an aggregate of 107,813 shares of Atara's common stock to five such newly hired

Business Wire
Neutral
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
2021-09-29 03:30

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the upcoming full release of new translational data and two-year open-label extension (OLE) clinical data from the study of ATA188 in progressive multiple sclerosis (MS). The findings will be presented as an ePoster at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place virtually October 13-15, 2021. The presentation includes n

Business Wire
Neutral
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
2021-09-27 08:30

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment to the Company's lead product candidate, tabelecleucel (tab-cel®), for the treatment of

Business Wire
Neutral
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-09-03 16:01

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 74,055 restricted stock units of Atara's common stock to 16 newly hired employees and stock options to purchase an aggregate of 59,869 shares of Atara's common stock to five such newly hired e

Business Wire
Neutral
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
2021-09-02 08:30

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a panel discussion titled, “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy,” at the Citi 16th

Seeking Alpha
Neutral
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2021 Results - Earnings Call Transcript
2021-08-09 22:50

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
2021-08-09 18:28

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -3.41% and -38.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
2021-08-09 16:02

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2021, recent business highlights and key catalysts over the next several months. “We are very pleased with the progress achieved across all of our programs and important clinical u

Loading more news...